Elan/Wyeth Move Novel Alzheimer’s Treatment Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Monoclonal antibody’s influence on beta amyloid in the brain could be disease-modifying.
You may also be interested in...
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.